

Pharmacy Drug Policy Checklist

POLICY NAME Xeomin (incobotulinumtoxin A) POLICY # 2377P

Criteria

Crite	eria for Coverage for Cervical Dystonia
	1.1 Alternative diagnoses ruled out including chronic neuroleptic treatment, contractures, and other neuromuscular disorders
	1.2 Involuntary contractions of the neck muscles
	1.3 Chronic head torsion or tilt
	1.4 Symptoms present for at least 6 months
	1.5 Approval Time
	 Initial Approval: 4 procedures, repeated no more frequently than every 12 weeks within 12 months
	• Subsequent Approvals: 4 procedures, repeated no more frequently than every 12 weeks

Criteria for Coverage for Blepharospasm 2.1 Previous treatment with Botox 2.2 Approval Time Initial Approval: 4 procedures, repeated no more frequently than every 12 weeks within 12 months Subsequent Approvals: 4 procedures, repeated no more frequently than every 12 weeks

Criteria for Coverage for Upper Limb Spasticity		
	3.1 Documented focal wrist, elbow, or finger spasticity which originated at least 6 weeks post-cerebrovascular event (CVE) or progression of multiple sclerosis	
	3.2 Difficulty maintaining hygiene, dressing or pain	
	 3.3 Documented failure, intolerance, or contraindication to oral antispasmodics and muscle relaxants; Baclofen Tizanidine Cyclobenzaprine Methocarbamol Carisoprodol 	
	3.4 Sufficient motivation and cognitive function to actively participate in physical therapy post injection	
	3.5 No documented fixed contractures or profound muscle atrophy	
	3.6 Member will not receive treatment with phenol, alcohol, or surgery	
	 3.7 Approval Time Initial Approval: 4 procedures, repeated no more frequently than every 12 weeks within 12 months Subsequent Approvals: 4 procedures, repeated no more frequently than every 12 weeks 	
Coverage for Sialorrhea		

Coverage for Sialorrhea		
	4.1 Age 2 years or older	
	 4.2 Documented diagnosis of one of the following: Parkinson's Disease Amyotrophic Lateral Sclerosis (ALS) Criteria Statement of the Policy References Cerebral Palsy Stroke 	
	 4.3 Documented failure or intolerance to one of the following therapies: Glycopyrrolate Amitriptyline Hyoscyamine Sublingual ipratropium Sublingual atropine 	
	 4.4 Approval Time Initial Approval: 4 procedures, repeated no more frequently than every 12 weeks within 12 months Subsequent Approvals: 4 procedures, repeated no more frequently than every 12 weeks CPT Codes HCPCS Codes J0588 Injection, incobotulinumtoxin A [Xeomin] 	